Welcome!
Hyphens Pharma International
Broker's Calls
Brokers’ Digest: AEM, Prime US REIT, Hyphens Pharma, Seatrium, Valuetronics, DFI Retail Group, CDG, Centurion, Sembcorp
Here's what the analysts have to say this week.
7 days ago
Broker's Calls
CGS International lowers Hyphens Pharma’s TP to 35 cents amid slowing revenue momentum
Analyst Tay Wee Kuang has retained his “add” call on the company as he sees potential for higher contributions from new products within its portfolio
10 days ago
Results
Hyphens Pharma’s NPAT down 5.6% y-o-y at $2 mil for 3QFY2024
The group’s revenue was up 2.5% y-o-y at $43.9 million in 3QFY2024.
16 days ago
Broker's Calls
Brokers’ Digest: Hyphens Pharma International, MPACT, SGX Group
See what the analysts have to say this week.
September 12, 2024
Broker's Calls
CGSI ups Hyphens Pharma’s TP on ‘healthy pipeline’ of products ahead
CGS International analyst Tay Wee Kuang believes this will support patmi growth.
September 11, 2024
Contracts
Hyphens Pharma subsidiary enters into exclusive licensing agreement with Maruho for shingles medication
The agreement is for the exclusive rights to register and commercialise Amenalief in the 10 Asean countries.
June 05, 2024
Broker's Calls
SAC Capital’s optimism intact on Hyphens Pharma following 1QFY2024 results
The analysts' positive outlook remains unchanged, expecting the announced initiatives to proceed as planned.
May 21, 2024
Broker's Calls
Analysts like Hyphens Pharma as FY2023 net profit come in above expectations
CGS International and PhillipCapital have kept their 'add' and 'buy' calls. They both have target prices of 35 cents on the stock.
March 14, 2024
Broker's Calls
CGS-CIMB maintains ‘add’ on Hyphens Pharma at lowered target price
Hyphens' gross profit margin showed a 4.8% y-o-y decline to 35.4% in 3QFY2023, which it attributes to inflationary cost pressures.
November 28, 2023